Generated: April 29, 2017
|Title:||Crystalline pharmaceutical and methods of preparation and use thereof|
|Abstract:||Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention. ##STR00001##|
|Inventor(s):||Burnier; John (Pacifica, CA), Gadek; Thomas (Oakland, CA), Naud; Frederic (Binningen, CH)|
|Assignee:||SARcode Bioscience Inc. (Brisbane, CA)|
|Filing Date:||Dec 11, 2012|
|Claims:||1. A method of synthesizing a compound of Formula I: ##STR00028## comprising the steps: a) hydrogenolyzing an ester of Formula A with a palladium catalyst and a source of protons; and ##STR00029## b) isolating a compound of Formula I. |
2. The method of claim 1, wherein the palladium catalyst is 10% palladium on carbon.
3. The method of claim 1, wherein the proton source is formic acid.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.